pharmaceuticals
Bristol-Myers Q2 earnings, revenue top Street; stock dips on weak guidance
Biopharma company Bristol-Myers Squibb (NYSE: BMY) on Thursday reported higher earnings and revenues for the second quarter, The results also…
Earnings: Alexion Pharma Q2 results top expectations; raises FY19 guidance
Alexion Pharmaceuticals (Nasdaq: ALXN) reported a 28% growth for its second-quarter earnings, helped by an increase in revenues. The results…
These deals set a new paradigm for healthcare industry
After a busy 2018, the scale of merger and acquisition activity in the healthcare industry is expected to be high…
Looming opioid epidemic calls for stricter drug regulation
Though the healthcare industry is slowly waking up to the hazards of opioid-based prescription drugs, their sale continues unabated across…
Novartis’ one-time gene therapy for spinal muscular atrophy gets FDA nod
Picture Courtesy: Novartis Zolgensma, a gene-based treatment from Novartis (NYSE: NVS) for the treatment of spinal muscular atrophy that affects…
Earnings preview: Amarin likely to deliver strong Q4 results
Amarin Corporation (AMRN) is scheduled to report earnings results for the fourth quarter of 2018 on Wednesday, February 27, before…
Arrowhead Pharmaceuticals reports a loss of 12 cents per share in Q4
Arrowhead Pharmaceuticals (ARWR) reported Q4 and fiscal 2018 earnings results after the bell today. For the fourth quarter ended September 30,…
Pfizer pares recent gains after JP Morgan slashes rating
The outlook for Pfizer (PFE) remains mixed as the drug maker gears up for a closely-followed leadership change early next…
Teva’s shares soar on better-than-expected Q3 results and higher guidance
Teva Pharmaceutical Industries Ltd. (TEVA) saw its stock gain over 6.8% during premarket hours on Thursday after the company surpassed…
Humana beats on Medicare Advantage plans, raises outlook
Health insurer Humana (HUM) today reported its second-quarter earnings that surpassed analysts’ forecast, mainly due to surge in enrollment in…
Is Johnson & Johnson a ‘sell’ in 2018?
Johnson & Johnson may not be having a great 2018 so far with the stock ticking down about 8% since…